ClinicalTrials.gg
RecruitingNCT06882785Updated Nov 2, 2026

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

A Phase 3 interventional study of KarXT and Placebo in Schizophrenia, sponsored by Bristol-Myers Squibb. Recruiting at 56 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 2, 20263 sites added3 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing xanomeline in Schizophrenia — 9 open to participants now, 9 under way, 4 of them phase 3. xanomeline · Schizophrenia.

Planned enrollment
8th of 20
250 · median 178
Started
2025
with 3 others
Phase 3
14 of 20
4 open now
Registered
11th of 20
by date
Lead sponsor
4 of 20
Bristol-Myers Squibb

Among the 20 studies testing xanomeline in Schizophrenia, this one is the 8th largest by planned enrollment, is one of 4 that started in 2025, is one of 14 in phase 3, and was the 11th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

9 of the 20 studies testing xanomeline in Schizophrenia are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing xanomeline in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of KarXT in acutely psychotic Japanese adult participants with schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a primary diagnosis of schizophrenia established by a comprehensive psychiatric evaluation based on the ⎯Fifth Edition (DSM-5) criteria and confirmed by Mini International Neuropsychiatric Interview (MINI).
  • Participants must have a PANSS total score between 80 and 120, inclusive.
  • Participants must have a CGI-S score of ≥ 4.

Exclusion criteria

Exclusion Criteria

  • Participants must not have any primary disorder other than schizophrenia within 12 months before screening.
  • Participants must not be newly diagnosed or experiencing their first treated episode of schizophrenia.
  • Participants must not have any history or presence of medical conditions.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Administration of KarXT

    Drug: KarXT

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    Specified dose on specified days

    Also known as: BMS-986510

  • OtherPlacebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score

    Double-Blind Part

    Time frame: At week 5

  2. Number of participants with treatment-emergent adverse events (TEAEs)

    Open-label extension (OLE) Part

    Time frame: At Week 52 from OLE baseline

Secondary outcomes

  1. Change from baseline in PANSS positive score

    Double-blind Part

    Time frame: At week 5

  2. Change from baseline in PANSS negative score

    Double-blind Part

    Time frame: At week 5

  3. Change from baseline in PANSS Negative Marder Factor score

    Double-blind Part

    Time frame: At week 5

  4. Change from baseline in Clinical Global Impressions-Severity (CGI-S) score

    Double-blind Part

    Time frame: At week 5

  5. The percentage of PANSS responders (a ≥ 30% change in PANSS total score)

    Double-blind Part

    Time frame: At week 5

  6. Number of participants wtih adverse events (AEs)

    Double-blind Part

    Time frame: Up to day 35

  7. Number of participants wtih adverse events of special interest (AESIs)

    Time frame: Up to week 57

  8. Number of participants with procholinergic symptoms

    Time frame: Up to week 57

  9. Number of participants with anticholinergic symptoms

    Time frame: Up to week 57

  10. Change from baseline in Simpson-Angus Scale (SAS) score

    Double-blind Part

    Time frame: Up to day 35

  11. Change from baseline in Barnes Akathisia Rating Scale (BARS) score

    Double-blind Part

    Time frame: Up to day 35

  12. Change from baseline in Abnormal Involuntary Movement Scale (AIMS) score

    Double-blind Part

    Time frame: Up to day 35

  13. Change from baseline in body weight

    Double-blind Part

    Time frame: Up to day 35

  14. Change from baseline in body mass index (BMI)

    Double-blind Part

    Time frame: Up to day 35

  15. Blood pressure (BP) sitting and standing after 2 minutes

    Time frame: Up to week 57

  16. Heart rate (HR) sitting and standing after 2 minutes

    Time frame: Up to week 57

  17. Number of participants wtih a change from baseline in hematology evaluations

    Time frame: Up to week 57

  18. Number of participants wtih a change from baseline in clinical chemistry evaluations

    Time frame: Up to week 57

  19. Number of participants wtih a change from baseline in coagulation evaluations

    Time frame: Up to week 57

  20. Number of participants wtih a change from baseline in urinalysis evaluations

    Time frame: Up to week 57

  21. Number of participants wtih a change from baseline in drug screen evaluations

    Time frame: Up to week 57

  22. Number of participants wtih a change from baseline in 12-lead electrocardiogram (ECG) evaluations

    Time frame: Up to week 57

  23. Number of participants wtih physical examination abnormalities

    Time frame: Up to week 57

  24. Number of participants wtih suicidal ideation with the use of the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to week 57

  25. International Prostate Symptom Score (IPSS)

    Male participants ≥ 45 years of age only

    Time frame: Up to week 57

  26. Area under the plasma concentration-time curve (AUC)

    Double-blind Part

    Time frame: Up to day 35

  27. Maximum observed plasma concentration (Cmax)

    Double-blind Part

    Time frame: Up to day 35

  28. Time of maximum observed plasma concentration (Tmax)

    Double-blind Part

    Time frame: Up to day 35

  29. Number of participants wtih serious TEAEs

    OLE Part

    Time frame: Up to week 57

  30. Number of participants wtih TEAEs leading to discontinuation of study intervention

    OLE Part

    Time frame: Up to week 57

  31. Change from OLE baseline in PANSS total score

    OLE Part

    Time frame: At week 57

  32. Change from OLE baseline in CGI-S score

    OLE Part

    Time frame: At week 57

  33. Percentage of PANSS responders

    OLE Part

    Time frame: At week 57

07

Study locations

46 of 56 sites recruiting
  • Hotei Hospital
    Kōnan, Aichi-ken 4838248, Japan
    Recruiting
    • Takakura Masashi, Site 0034 · Contact+81587557251
  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
    Recruiting
    • Hiroshige Fujishiro, Site 0056 · Contact0527442282
  • Okehazama Hospital
    Toyoake, Aichi-ken 470-1168, Japan
    Recruiting
    • kiyoshi Fujita, Site 0001 · Contact0562971361
  • Fujita Health University
    Toyoake, Aichi-ken 470-1192, Japan
    Recruiting
    • Taro Kishi, Site 0003 · Contact+81-562-93-2139
  • National Kohnodai Medical Center.
    Ichikawa, Chiba 272-8516, Japan
    Recruiting
    • Toshihiko Ito, Site 0009 · Contact+81-47-372-3501
  • Local Institution - 0032
    Iizuka, Fukuoka 820-0014, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0037
    Kitakyushu, Fukuoka 803-0831, Japan
    Not yet recruiting
    • Site 0037 · Contact
  • Shiranui Hospital
    Omuta, Fukuoka 836-0004, Japan
    Recruiting
    • Michihiko Matsushita, Site 0016 · Contact81-944-55-2000
  • Takeda General Hospital - Aizuwakamatsu
    Aizu-Wakamatsu, Fukushima 965-0876, Japan
    Recruiting
    • Koichi Osonoe, Site 0042 · Contact81242275511
  • Holy Cross Hospital - Toki
    Toki, Gifu 509-5142, Japan
    Recruiting
    • Hideaki Tabuse, Site 0044 · Contact0572-54-8181
  • Kure Medical Center
    Kure, Hiroshima 737-0023, Japan
    Recruiting
    • Wataru Omori, Site 0007 · Contact0823223111
  • Goryokai Medical Corporation - Goryokai Hospital
    Sapporo, Hokkaido 002-8029, Japan
    Recruiting
    • Kimihiro Nakajima, Site 0004 · Contact+81-11-771-5660
  • Hokkaido University Hospital
    Sapporo, Hokkaido 0608648, Japan
    Recruiting
    • Naoki Hashimoto, Site 0049 · Contact81117067600
  • Local Institution - 0025
    Hadano-shi, Kanagawa 257-0003, Japan
    Not yet recruiting
    • Site 0025 · Contact
  • Fujimidai Hospital
    Hiratsuka, Kanagawa 259-1205, Japan
    Recruiting
    • Takafumi Yahoko, Site 0040 · Contact+81-463-58-0186
  • Kitasato University Hospital
    Sagamihara, Kanagawa 252-0375, Japan
    Recruiting
    • Ken Inada, Site 0052 · Contact+81-42-778-8111
  • Tsurumi Nishii Hospital
    Yokohama, Kanagawa 230-0074, Japan
    Recruiting
    • Herbert Nishii, Site 0023 · Contact045-581-3055
  • Yokohama City University Medical Center
    Yokohama, Kanagawa 232-0024, Japan
    Recruiting
    • Nobuhiko Noguchi, Site 0028 · Contact81452615656
  • Hino Hospital - Yokohama
    Yokohama, Kanagawa 234-0051, Japan
    Recruiting
    • Atsuomi Baba, Site 0035 · Contact+81-45-843-8511
  • Yuge Hospital
    Kumamoto, Kumamoto 861-8002, Japan
    Recruiting
    • Masahiro Shono, Site 0011 · Contact81-96-338-3838
  • Local Institution - 0019
    Yatsushiro, Kumamoto 866-0043, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • National Hospital Organization Maizuru Medical Center
    Maizuru, Kyoto 625-8502, Japan
    Recruiting
    • Sumihiro Yamano, Site 0046 · Contact81773622680
  • Miyakonojo Shinsei Hospital
    Miyakonojō, Miyazaki 885-0093, Japan
    Recruiting
    • Masahiko Kawano, Site 0017 · Contact+81-986-22-0280
  • Local Institution - 0014
    Komoro, Nagano 384-8540, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 0050
    Matsumoto, Nagano 390-0847, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of the Ryukyus Hospital
    Ginowan, Okinawa 901-2725, Japan
    Recruiting
    • Hotaka Shinzato, Site 0051 · Contact+8198-894-1301
  • Osaka Psychiatric Medical Center
    Hirakata, Osaka 573-0022, Japan
    Recruiting
    • Taro Matsuda, Site 0022 · Contact072-847-3261
  • Kansai Medical University Medical Center
    Moriguchi, Osaka 570-8507, Japan
    Recruiting
    • SHUNICHIRO IKEDA, Site 0026 · Contact0669921001
  • Nagaokai Medical Corporation - Neyagawa Sanatorium
    Neyagawa, Osaka 572-0854, Japan
    Recruiting
    • Naohiko Matsumoto, Site 0021 · Contact0728223561
  • Shin-Abuyama Hospital
    Takatsuki, Osaka 569-1041, Japan
    Recruiting
    • Hiroki Kikuyama, Site 0005 · Contact+81726931881
  • Osaka Medical and Pharmaceutical University Hospital
    Takatsuki, Osaka 569-8686, Japan
    Recruiting
    • Tetsufumi Kanazawa, Site 0024 · Contact072-683-1221
  • Rainbow and Sea Hospital
    Karatsu-shi, Saga-ken 847-0031, Japan
    Recruiting
    • Taro Shindo, Site 0010 · Contact0955770711
  • Inuo Hospital
    Tosu, Saga-ken 841-0081, Japan
    Recruiting
    • Akifumi Inuo, Site 0038 · Contact0942827007
  • Saitama Konan Hospital
    Kumagaya, Saitama 360-0114, Japan
    Recruiting
    • Narifumi Yokoyama, Site 0020 · Contact048-536-1366
  • Dokkyo Medical University Hospital
    Shimotsuga, Tochigi 321-0293, Japan
    Recruiting
    • Norio Furukori, Site 0047 · Contact0282861111
  • Local Institution - 0054
    Shimotsuke, Tochigi 329-0498, Japan
    Not yet recruiting
    • Site 0054 · Contact
  • Tochigi Prefectural Okamotodai Hospital
    Utsunomiya, Tochigi 3291104, Japan
    Recruiting
    • Taku Amano, Site 0043 · Contact81-28-673-2211
  • Local Institution - 0012
    Hachiōji, Tokyo 192-0153, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • National Center of Neurology and Psychiatry
    Kodaira, Tokyo 187-8551, Japan
    Recruiting
    • Kyoji Okita, Site 0002 · Contact042-341-2711
  • Asuka Hospital
    Machida, Tokyo 1940005, Japan
    Recruiting
    • yoshie tamura, Site 0027 · Contact042-795-2080
  • Toho University Omori Medical Center
    Ōta-ku, Tokyo 143-8541, Japan
    Recruiting
    • Takahiro Nemoto, Site 0053 · Contact03-3762-4151
  • Tokyo Metropolitan Matsuzawa Hospital
    Setagaya City, Tokyo 1560057, Japan
    Recruiting
    • Keiko Genda, Site 0045 · Contact0333037211
  • Narimasu Kosei Hospital
    tabashi City, Tokyo 175-0091, Japan
    Recruiting
    • Yuya Tenjin, Site 0013 · Contact0339391191
  • Yamaguchi University Hospital
    Ube, Yamaguchi 755-8505, Japan
    Recruiting
    • Fumihiro Higuchi, Site 0036 · Contact81836222111
  • National Hospital Organization Shimofusa Psychiatric Medical Center
    Chiba, 266-0007, Japan
    Recruiting
    • Teruki Koizumi, Site 0015 · Contact+81.43.291.1221
  • Kuramitsu Hospital
    Fukuoka, 819-0037, Japan
    Recruiting
    • Noriko Tamaru, Site 0008 · Contact+81-92-811-1821
  • University Hospital,Kyoto Prefectural University of Medicine
    Kyoto, 602-8566, Japan
    Recruiting
    • Anri WATANABE, Site 0048 · Contact+81-752515612
  • Miyazaki Prefectural Miyazaki Hospital
    Miyazaki, 880-8510, Japan
    Recruiting
    • Jiro Kawano, Site 0029 · Contact81985244181
  • Okayama University Hospital
    Okayama, 700-8558, Japan
    Recruiting
    • Shinji Sakamoto, Site 0055 · Contact+81-86-235-7242
  • Local Institution - 0018
    Okinawa, 904-0012, Japan
    Not yet recruiting
    • Site 0018 · Contact
  • Asakayama Hospital
    Osaka, 590-0018, Japan
    Recruiting
    • Norio Taniguchi, Site 0031 · Contact+81-72-229-4882
  • Saitama Neuropsychitric Institute
    Saitama, 338-8577, Japan
    Recruiting
    • Hakuei Yamashita, Site 0041 · Contact048-857-6811
  • Tokushima University Hospital
    Tokushima, 770-8503, Japan
    Recruiting
    • Tomohiko Nakayama, Site 0039 · Contact088-631-7130
  • Local Institution - 0033
    Tottori, 689-0203, Japan
    Withdrawn

    Not enrolling at this site — choose another above.

  • Wakayama Medical University Hospital
    Wakayama, 641-8510, Japan
    Recruiting
    • Sohei Kimoto, Site 0006 · Contact073-441-0659
  • Yamagata Sakuracho Hospital
    Yamagata, 990-0045, Japan
    Recruiting
    • Nobuhiro Yokokawa, Site 0030 · Contact+81236312315
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Sep 2028, 39 months after the start.

Of 99 industry-sponsored phase 3 interventional studies under Schizophrenia, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 41. This study's planned 39 months is above that.

Counting every sponsor, half of 113 studies reached it within 32 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2025
First posted
Mar 19, 2025
StartActual
Jun 10, 2025
Primary completionEst.
Sep 23, 2028
CompletionEst.
Aug 23, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed
Show 3 added (3 Japan)
  • Nagoya University Hospital · Nagoya, Japan
  • National Hospital Organization Shimofusa Psychiatric Medical Center · Chiba, Japan
  • Asakayama Hospital · Osaka, Japan
Show 3 removed
  • Local Institution - 0056 · Nagoya, Japan
  • National Hospital Organization Shimofusa Psychiatric Medical Center · MIdori-ku, Chiba-shi, Japan
  • Local Institution - 0031 · Osaka, Japan
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    3 sites added, 3 sites removed
    Show 3 added (3 Japan)
    • Nagoya University Hospital · Nagoya, Japan
    • National Hospital Organization Shimofusa Psychiatric Medical Center · Chiba, Japan
    • Asakayama Hospital · Osaka, Japan
    Show 3 removed
    • Local Institution - 0056 · Nagoya, Japan
    • National Hospital Organization Shimofusa Psychiatric Medical Center · MIdori-ku, Chiba-shi, Japan
    • Local Institution - 0031 · Osaka, Japan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06882785
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Jun 10, 2025
Primary completion
Sep 23, 2028 (estimated)
Completion
Aug 23, 2029 (estimated)
Last update
Nov 2, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion